Diabetes Management: Insulin Pumps Market (2020)
Diabetes Management: Insulin Pumps Market (2020)
$4,750.00
This report provides an overview of diabetes, automated insulin pump systems, and a comprehensive market and competitive analysis.
Publisher: Meddevicetracker
- Highlights
- Description
- Contents
Highlights
- Global sales of technologically advanced automated insulin pumps (including discreetly worn pod-patch-based insulin delivery systems and tubed-based hybrid closed-loop systems) for diabetes are expected to increase at a double-digit CAGR of 10.4%, from nearly $3.1bn in 2019 to approximately $5.1bn in 2024
- Unlike other medical device markets, insulin pumps sales have only been moderately affected by COVID-19 due to physician’s office closings due to the ability to conduct remote telemedicine visits and home-based use of pumps by patients
- The top 3 major competitors of insulin pump systems in 2019 were: Medtronic, Insulet Corporation, and Tandem Diabetes Care
- Several innovative startups (eg Beta Bionics, Diabeloop, and others) are planning to enter the market over the forecast period with improved, next-generation systems
- The multi-billion dollar insulin pumps market is vastly underpenetrated and will be driven by several positive factors, including the large and increasing global prevalence of diabetes, strong demand for smart, automated, Bluetooth/wireless connected continuous glucose monitoring (CGM) sensor-based insulin delivery technologies, and other ever-improving technological innovations
- Hybrid closed-loop systems (and in the future, nearly “closed-loop” autonomous systems, more similar in function to a human pancreas) can substantially improve glycemic control by continuously monitoring and predicting blood glucose levels, alerting users, preventing highs and lows, making intelligent, customized insulin delivery decisions based on a patient’s customized diet/exercise/lifestyle factors, lowering potential insulin dosing errors, protecting against nighttime hypoglycemia and adjusting for meal-related hyperglycemia or high blood glucose (eg with Autocorrect Bolus functions), and substantially improve time-in-range (TIR)
- Overall, automated insulin pumps can substantially lower diabetes complications resulting from potentially dangerous hypo- and hyperglycemic events experienced with traditional, painful multiple daily fingersticks and cumbersome manual daily insulin injections (MDI) prone to user error
- The US remains the largest market, with solid reimbursement, expanding awareness of the utility and long-term cost savings of automated insulin pump/pod systems supported by an expanding network of referral endocrinologists, heavy promotion/training efforts, and increasing US diabetes prevalence; however, Europe and other regions are also growth targets for manufacturers due to increasing diabetes cases and the need to control spiraling diabetes costs.
Key topics covered
- overview of diabetes
- insulin pump/pod/patch-based technologies, competitors, and portfolios
- technological innovations/pipelines, including next-generation automated pump systems
- in-depth market and competitive analyses (market drivers/limiters, 5-year market forecasts by segment and region, and global/regional market share)
- corporate overview and financials
- markets covered by this analysis include: the US, Japan, the five major European markets (France, Germany, Italy, Spain, and the UK), and the Rest of World (RoW) markets, which includes all other countries. Market forecasts are for the 2019-24 time period.
Overview
Despite the negative impact of COVID-19 on most medical device markets, the multi-billion dollar automated insulin pumps market for diabetes—which includes insulin pumps and disposable pump supplies and accessories—is thriving and is expected to increase at a healthy CAGR of 10.4%, from nearly $3.1bn in 2019 to an estimated $5.1bn in 2024.
The global insulin pumps market is technologically innovative, lucrative, and growing. The market is being driven by several positive factors, including: the increasing global prevalence of diabetes, the need to reduce patient burden, stress, and insulin dosing errors, replace frequent and painful fingersticks and continuously monitor blood glucose, and improve glycemic control. The rise of popularity of easy-to-use, discreetly worn “pod/patch” based insulin delivery systems (such as the Omnipod) and more sophisticated, “intelligent” continuous glucose monitoring (CGM) sensor-integrated, automated hybrid closed-loop insulin pump systems (eg MiniMed, t:slim X2) stems from the ability to substantially lower diabetes complications, improve clinical outcomes, provide patients more freedom, and substantially lower diabetes-related complications and healthcare costs. Automated insulin delivery devices can replace frequent painful fingersticks and manual multiple daily insulin injections (MDI) in an underpenetrated but large and growing diabetes population, improving quality of life.
The insulin pumps market is highly competitive, and manufacturers are in a race to capture market share. Competitors are offering easier-to-use, miniaturized, streamlined, artificial intelligence (AI)-driven Bluetooth wireless/smartphone-based devices that allow instant alerts and sharing of real-time data with caregivers. These devices integrate more accurate, longer-wear CGM sensors and other innovative features that can better predict and prevent glycemic events by factoring in numerous patient diet/lifestyle variables, lower potentially dangerous manual bolus dosing errors, and stabilize blood sugar levels for long-term glycemic control. Overall, these next-generation systems are becoming closer to autonomously “closed-loop” systems that are more similar to the natural and miraculous function of the human pancreas.
Key competitors in the insulin pumps market include: Medtronic, Insulet Corporation, Tandem Diabetes Care, Ypsomed, and a handful of smaller innovative startups such as Beta Bionics, Diabeloop, Bigfoot Biomedical, and others.
This comprehensive medical market and technology report provides:
- overview of type 1 and type 2 diabetes and prevalence
- automated insulin pump/pod/patch-based insulin delivery technologies
- portfolios and competitive advantages/features
- emerging technologies/pipelines and innovations
- in-depth market and competitive analyses (market drivers/limiters, 5-year market forecasts by segment and region, global/regional market share)
- overview of companies, financials, and strategic growth plans
Markets covered by this analysis include the US, Japan, the five major European markets (France, Germany, Italy, Spain, and the UK), and the Rest of World (RoW) markets, which includes all other countries. Market forecasts are for the 2019-24 time period.
Table of Contents
Executive Summary……………………………………………………………………………………………….. ES-1
i. Diabetes overview………………………………………………………………………………………………..ES-1
ii. Global diabetes prevalence…………………………………………………………………………………..ES-2
iii. Insulin pump technology……………………………………………………………………………………..ES-2
iv. Insulin pumps market………………………………………………………………………………………….ES-3
v. Market leaders……………………………………………………………………………………………………ES-7
vi. Bibliography …………………………………………………………………………………………………….ES-10
vii. Methodology …………………………………………………………………………………………………..ES-11
Exhibit ES-1: Insulin pumps, global market forecast ($m), 2019-24 ………………………………… ES-5
Exhibit ES-2: Insulin pumps market, forecast sales by region ($m), 2019-24…………………….. ES-6
Exhibit ES-3: Insulin pumps market, global share by supplier, 2019 ……………………………….. ES-8
Exhibit ES-4: Insulin pumps market, global share by supplier, 2020E………………………………. ES-9
1. Diabetes Overview ………………………………………………………………………………………………. 1-1
1.1 Prevalence………………………………………………………………………………………………………… 1-1
1.2 Diabetes…………………………………………………………………………………………………………… 1-2
1.2.1 Symptoms………………………………………………………………………………………….. 1-3
1.2.2 Complications …………………………………………………………………………………….. 1-4
1.2.3 Diagnosis and treatment………………………………………………………………………. 1-4
1.2.4 Cost of diabetes………………………………………………………………………………….. 1-6
1.3 Bibliography ……………………………………………………………………………………………………… 1-7
2. Automated Insulin Pumps …………………………………………………………………………………….. 2-1
2.1 Insulin pumps……………………………………………………………………………………………………. 2-4
2.1.1 Insulet Corporation……………………………………………………………………………. 2-13
2.1.2 Medtronic ………………………………………………………………………………………… 2-19
2.1.3 Roche ………………………………………………………………………………………………. 2-39
2.1.4 Tandem Diabetes Care……………………………………………………………………….. 2-40
2.1.5 Ypsomed ………………………………………………………………………………………….. 2-47
2.1.6 Valeritas…………………………………………………………………………………………… 2-50
2.2 Emerging artificial pancreas systems………………………………………………………………….. 2-51
2.2.1 Beta Bionics………………………………………………………………………………………. 2-54
2.2.2 Bigfoot Biomedical…………………………………………………………………………….. 2-55
2.2.3 Diabeloop…………………………………………………………………………………………. 2-58
2.2.4 EOFlow …………………………………………………………………………………………….. 2-61
2.3 Bibliography ……………………………………………………………………………………………………. 2-63
Exhibit 2-1: Leading automated insulin pump brands, by manufacturer, 2020 …………………… 2-6
Exhibit 2-2: Selected leading automated insulin pumps and hybrid closed-loop (“artificial pancreas”) systems, 2020…………………………………………………………. 2-7
Exhibit 2-3: The three-step Omnipod insulin delivery process……………………………………….. 2-14
Exhibit 2-4: The new Omnipod DASH………………………………………………………………………… 2-16
Exhibit 2-5: The MiniMed 670G hybrid closed-loop insulin pump…………………………………… 2-22
Exhibit 2-6: New MiniMed 770G and MiniMed 780G hybrid closed-loop insulin pumps…….. 2-33
Exhibit 2-7: The Tidepool Loop app for iPhone and Apple Watch …………………………………… 2-38
Exhibit 2-8: The Accu-Check Solo micropump system…………………………………………………… 2-39
Exhibit 2-9: The t:slim X2 insulin pump with Basal-IQ technology ………………………………….. 2-42
Exhibit 2-10: The t:slim X2 insulin pump with Control-IQ technology and Automatic
Correction Bolus Function …………………………………………………………………….. 2-45
Exhibit 2-11: The mylife YpsoPump system………………………………………………………………… 2-48
Exhibit 2-12: The mylife Assist system ………………………………………………………………………. 2-49
Exhibit 2-13: The V-Go 24-hour wearable insulin delivery device for type 2 diabetes………… 2-50
Exhibit 2-14: Selected companies/startups developing artificial pancreas systems, 2020…… 2-51
Exhibit 2-15: Selected artificial pancreas systems under development, 2020 …………………… 2-52
Exhibit 2-16: The Bigfoot Unity Diabetes Management Program……………………………………. 2-57
Exhibit 2-17: The Diabeloop DBLG1 hybrid closed-loop system……………………………………… 2-59
Exhibit 2-18: The EOPatch……………………………………………………………………………………….. 2-62
3. Market Analysis…………………………………………………………………………………………………… 3-1
3.1 Insulin pumps market ………………………………………………………………………………………… 3-1
3.1.1 Market forecast: global………………………………………………………………………… 3-1
3.1.2 Market drivers and limiters ………………………………………………………………….. 3-4
3.1.3 Market forecast: by region …………………………………………………………………… 3-6
3.1.4 US market ………………………………………………………………………………………….. 3-8
3.1.5 Five major European markets……………………………………………………………….. 3-8
3.1.6 Japanese market…………………………………………………………………………………. 3-9
3.1.7 Rest of the world market……………………………………………………………………… 3-9
3.2 Competitive analysis………………………………………………………………………………………….. 3-9
3.2.1 Market share: global……………………………………………………………………………. 3-9
3.2.2 Market share by region………………………………………………………………………. 3-15
3.3 Company financials………………………………………………………………………………………….. 3-17
3.3.1 Insulet Corporation……………………………………………………………………………. 3-17
3.3.2 Medtronic ………………………………………………………………………………………… 3-19
3.3.3 Tandem Diabetes Care……………………………………………………………………….. 3-30
3.4 Bibliography ……………………………………………………………………………………………………. 3-34
Exhibit 3-1: Insulin pumps, global market forecast ($m), 2019-24 ……………………………………. 3-2
Exhibit 3-2: Insulin pumps market, estimated sales and share of revenues by region, 2019 …. 3-6
Exhibit 3-3: Insulin pumps market, forecast sales by region ($m), 2019-24………………………… 3-7
Exhibit 3-4: Insulin pumps market, global share by supplier, 2019 …………………………………. 3-10
Exhibit 3-5: Insulin pumps market, global share by supplier, 2020E ……………………………….. 3-11
Exhibit 3-6: Insulin pumps market, estimated share by supplier and region, 2019 ……………. 3-16
Exhibit 3-7: Insulet, revenues by segment, FY2019………………………………………………………. 3-19
Exhibit 3-8: Medtronic, revenues by segment, FY2019-FY2020 ……………………………………… 3-29
Exhibit 3-9: Tandem Diabetes Care, revenues by segment, FY2019 ………………………………… 3-33
Appendix A: company listing
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Company Analysis: GlaxoSmithKline 
Sign up to the